Thibault HONEGGER

NETRI is an industrial start-up that designs and manufactures standardized neuro organs-on-chip for life-science companies focused on neurological disorders, pain and dermo-cosmetics.

NETRI offers R&D services and commercializes organs-on-chip devices for R&D departments and CROs in pre-clinical stages. NETRI's products and services are used to anticipate the efficacy of innovative treatments, accelerate preclinical research phases, and reposition compounds on new indications, all the while limiting animal testing.

Its patented technologies make use of repeatable human neural circuits coupled with multiple human cell types. This opens the way for more effective high-throughput screening of compounds by allowing the creation of predictive human-based models.

With more than 45 collaborators, including 12 PhDs part of a mutlidisciplinary team (engineering, biology and digital), NETRI is located in Lyon (France) with 300 m² of clean room facilities and P2 labs. In 2022, NETRI secured a Series A funding of 8 million euros and is currently closing a Series B round to support its industrial and international growth.

For more information: netri.com/